These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 3896821)
1. Inhibition of thromboxane and 12-HPETE formation by dazoxiben and its two thiophenic acid-substituted derivatives. Smith EF; Darius H; Ferber H; Schrör K Eur J Pharmacol; 1985 Jun; 112(2):161-9. PubMed ID: 3896821 [TBL] [Abstract][Full Text] [Related]
2. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour. Parry MJ Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997 [TBL] [Abstract][Full Text] [Related]
3. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related]
4. Effect of dazoxiben on platelet-vessel wall interaction. Davies JA; Menys VC Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):45S-46S. PubMed ID: 6681703 [TBL] [Abstract][Full Text] [Related]
5. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides. Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780 [TBL] [Abstract][Full Text] [Related]
6. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid. Patscheke H Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373 [TBL] [Abstract][Full Text] [Related]
7. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
8. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421 [TBL] [Abstract][Full Text] [Related]
9. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction. De La Cruz JP; Villalobos MA; Escalante R; Guerrero A; Arrebola MM; Sánchez de La Cuesta F Br J Pharmacol; 2002 Dec; 137(7):1082-8. PubMed ID: 12429581 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products. Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554 [TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. Menys VC; Davies JA Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575 [TBL] [Abstract][Full Text] [Related]
12. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. O'Keefe EH; Liu EC; Greenberg R; Ogletree ML Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501 [TBL] [Abstract][Full Text] [Related]
13. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Dale J; Thaulow E; Myhre E; Parry J Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091 [TBL] [Abstract][Full Text] [Related]
14. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Gresele P; Deckmyn H; Huybrechts E; Vermylen J Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299 [TBL] [Abstract][Full Text] [Related]
15. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. FitzGerald GA; Brash AR; Oates JA; Pedersen AK J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181 [TBL] [Abstract][Full Text] [Related]
16. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions. Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391 [TBL] [Abstract][Full Text] [Related]
17. Effect of the thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. Schumacher WA; Lucchesi BR J Pharmacol Exp Ther; 1983 Dec; 227(3):790-6. PubMed ID: 6418881 [TBL] [Abstract][Full Text] [Related]
18. The effects of dazoxiben, an inhibitor of thromboxane synthetase, on cold-induced forearm vasoconstriction and platelet behaviour in different individuals. Cowley AJ; Jones EW; Carter AJ; Hanley SP; Heptinstall S Br J Clin Pharmacol; 1985 Jan; 19(1):1-8. PubMed ID: 2983748 [TBL] [Abstract][Full Text] [Related]
19. RCS from human platelets: is it only thromboxane? Smith EF; Rücker W; Schrör K Eur J Pharmacol; 1983 Nov; 95(1-2):121-4. PubMed ID: 6667711 [TBL] [Abstract][Full Text] [Related]
20. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function. Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]